At 9 am this morning, Dendreon Corporation (Nasdaq: DNDN) announced the long awaited interim analysis of the Phase 3, randomized, double-blind, placebo-controlled IMPACT (Immunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B). The clinical trial is designed to assess the safety and efficacy of the investigational active cellular immunotherapy Provenge® (sipuleucel-T) in men with metastatic [...]
GTx, Inc. (Nasdaq: GTXI) has conducted a number of clinical trials using toremifene citrate in both the treatment of breast and prostate cancer. Older women and men as well as women and men being treated for both breast and prostate cancers are subject to bone loss leading to an increased risk of falls and fractures. [...]
High Intensity Focused Ultrasound (HIFU) is a minimally invasive procedure that uses ultrasound energy to destroy cancerous tissue with focused sound waves. It has been used for a period of time in both Europe and Mexico as a primary prostate cancer treatment. Currently, in the United States there is a phase III trial being conducted [...]
Once we develop metastatic androgen-independent prostate cancer and experience disease progression after receiving docetaxel-based chemotherapy we have no approved treatment options. We have hit the proverbial wall! In the process of attempting to develop additional treatments, ImClone Systems Inc. (NASDAQ: IMCL), announced the beginning of a Phase II clinical trial for men with advanced prostate [...]
As my regular readers probably have noted from prior posts, I am a strong advocate for research and the development of a prostate cancer vaccine. A cancer vaccine is different from the more “common” types of vaccines that are familiar to us. The “common” vaccines (i.e. tetanus or polio) are administered prior to having an [...]
At the last ASCO Annual Meeting Saad et al. presented a report about a Phase II trial of custirsen (OGX-011) + docetaxel + prednisone vs. custirsen + mitoxantrone + prednisone in metastatic hormone-refractory prostate cancer. The subjects in the study had experienced relapses of cancer progression within 6 months of treatment with first-line docetaxel therapy. [...]
The last few days have seen a lot of commotion and celebrating in the prostate cancer world. There have been multiple news stories of an experimental prostate cancer drug, abiraterone, that has been reported to dramatically shrink prostate cancer tumors and extend survival in 70 to 80 percent of men with aggressive prostate cancer. Abiraterone [...]
See the end of this post for information about additional trials that are using Ipilimumab and currently recruiting men with hormone refractory prostate cancer. A multi-site PHASE I study with 33 men has found that a drug called Ipilimumab, also known as MDX-010, has been shown to be able to stimulate the body's own immune [...]
I have been very negligent in not writing about my experience at the American Association of Cancer Researchers (AACR) annual meeting that I attended last month. I found that there was so much information, experiences and emotions that I came away feeling very awed and somewhat over whelmed by the experience. I am still [...]
One of the options for treatment your oncologist may recommend is for you to participate in a clinical trial. Clinical trials are carefully designed research studies that answer specific questions regarding the effectiveness and safety of new drugs, combinations of drugs, treatments, surgical techniques, or medical devices. Human volunteers with specific health conditions are studied [...]
